Instructions for Klacid (Clarithromycin) pills
English product name
Klacid®
Release Form
tab. film sheath, 250 mg: 10, 14 or 20 pcs.
tab. film sheath, 500 mg: 7, 10, 14, 20, 21, 28, 30 or 42 pcs.
Description
The tablets are covered with a film shell of light yellow color, oval, double-convex.
1 tab.
clarithromycin 500 mg
Adjuvants:
Sodium Croskarmellosis - 65.6 mg, Microcrystalline cellulose - 183.9 mg, Silicon dioxide - 12 mg, Povidone (K29-32) - 25.5 mg, Stearic acid - 21 mg, Magnesium stearate - 12.6 mg, Talc - 29.4 mg.
The film sheath consists of hypromellose (hydroxypropylmethylcellulose) - 22.1 mg, hyprolose - 1.7 mg, propylene glycol - 14.62 mg, sorbitana oleate - 1.7 mg, titanium dioxide - 5.1 mg, sorbic acid - 0.94 mg, vanillin - 0.94 mg, dye quinoline yellow (E104) - 0.07 mg.
ATC codes
J01FA09 Clarithromycin
Clinical-pharmacological groups / Group affiliation
macrolide groups
Active substance
clarithromycin
Pharmaco-therapeutic group
macrolide
Storage Conditions
The drug antimicrobial should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C.
Best before date
The shelf life is three years. Do not apply after the expiry date indicated on the package.
Pharmacological effect
A semi-synthetic antimicrobial of the macrolide group. It has an antibacterial effect by interacting with the 50S ribosomal subunit and inhibiting the synthesis of the protein of bacteria that are sensitive to it.
Clarithromycin demonstrated high activity of in vitro in relation to both standard laboratory strains of bacteria and isolated in patients during clinical practice. It is highly active in many aerobic and anaerobic gram-positive and gram-negative microorganisms. The minimum suppressive concentrations (MPC) of clarithromycin for most pathogens are less than the erythromycin MPC on average per log2 dilution.
Testimony
- Infectious inflammatory diseases caused by clarithromycin-sensitive microorganisms in adults and children over twelve:
- lower respiratory tract infections (such as bronchitis, pneumonia);
- upper respiratory tract infections (such as pharyngitis, sinusitis);
- Skin and soft tissue infections (such as folliculitis, subcutaneous inflammation, and horn);
- disseminated or localized mycobacterial infections caused by Mycobacterium avium and Mycobacterium intracellulare;
- localized infections caused by Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium kansasii;
- Prevention of Mycobacterium avium (MAC) infection in HIV-infected patients with CD4 lymphocytes (T-helper lymphocytes) not
- xceeding 100 in 1 mm3;
- Helicobacter pylori eradication and reduction of recurrence of duodenal ulcer;
- odontogenic infections.
Method of use, course and dosage
The drug is ingested regardless of the intake of food.
Adults and children over twelve years old - one tab. (250 mg) twice a day (in this case it is possible to use the drug Clacid® film-coated tablets, two hundred and fifty mg). Clarithromycin five hundred mg is used twice a day for more severe infections. The duration of treatment is usually between five and fourteen
- Nosology (ICD codes)
- A31.9
- Infection caused by Mycobacterium, unspecified
- A46
- Rozha
- A48.1
- Legionnaires' disease
- B20.0
- HIV-related disease with mycobacterial infection
- B98.0
- Helicobacter pylori as the cause of diseases classified in other categories
- J01
- Acute sinusitis
- J02
- Acute pharyngitis
- J03
- Acute tonsillitis
- J04
- Acute laryngitis and tracheitis
- J15
- Bacterial pneumonia not classified elsewhere
- J15.7
- Pneumonia caused by Mycoplasma pneumoniae
- J16.0
- Chlamydia-induced pneumonia
- J20
- Acute bronchitis
- J31.2
- Chronic pharyngitis
- J32
- Chronic sinusitis
- J35.0
- Chronic tonsillitis
- J37
- Chronic laryngitis and laryngotracheitis
- J42
- Chronic bronchitis unspecified
- K04
- Diseases of the pulp and periapical tissues (including periodontitis)
- K25
- Stomach ulcer
- K26
- Duodenum ulcer
- K27
- Peptic ulcer
- L01
- Impetigo
- L02
- Skin abscess, boils and carbuncles
- L03
- Phlegmona
- L08.0
- Piodermia
- L08.8
- Other Refined Local Skin and Subcutaneous Fibre Infections
- L73.9
- Hair follicle disease unspecified
- T79.3
- Post-traumatic wound infection not classified elsewhere
- Z29.2
- Another type of preventive chemotherapy (antimicrobial administration for preventive purposes)
